Dr Fabiana Corsi-Zuelli discusses the differences in immune cell counts in patients with schizophrenia compared to controls; highlighting a recent meta-analysis by Dudeck et al. (2025) that reinforces the growing consensus that immune dysfunction plays a role in schizophrenia.
[read the full story...]
Joe Pierre reports on the first published study exploring the relationship between antipsychotic dose and risk of relapse in first episode schizophrenia, which suggests that standard antipsychotic dosing is best for relapse prevention.
[read the full story...]
Shuichi Suetani and Jon Paul Teo discuss the International Research Program on Psychotic Disorders in Diverse Settings (INTREPID II) study, which investigates the epidemiology of untreated psychoses in 3 diverse settings in the Global South.
[read the full story...]
Elwira Lubos writes her debut blog on a recent systematic review with pairwise and network meta-analyses, looking at antipsychotic drugs for the acute treatment of patients with first episode schizophrenia.
[read the full story...]
Raphael Underwood summarises the NEURAPRO trial, which concludes that Omega-3 fatty acids are no better than placebo at preventing transition to psychosis in young people at ultrahigh risk for psychotic disorders.
[read the full story...]
Matthew Broome writes his debut Mental Elf blog on a three-year clinical and functional outcome comparison between first episode manic psychosis and first-episode schizophrenia.
[read the full story...]
Samei Huda presents the findings of a new meta-analysis, which explores the prognostic significance of competing ways of defining and measuring brief psychotic episodes.
[read the full story...]
